A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
NCT04137289
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
110
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastrointestinal Neoplasms
Cholangiocarcinoma
Pancreatic Neoplasms
Interventions
DRUG:
BI 905711
Sponsor
Boehringer Ingelheim